Abstract

Due to late diagnosis, high incidence of metastasis, and poor survival rate, pancreatic cancer is one of the most leading cause of cancer-related death. Although manifold recent efforts have been done to achieve an early diagnosis of pancreatic cancer, CA-19.9 is currently the unique biomarker that is adopted for the detection, despite its limits in terms of sensitivity and specificity. To identify potential protein biomarkers for pancreatic ductal adenocarcinoma (PDAC), we used three model liposomes as nanoplatforms that accumulate proteins from human plasma and studied the composition of this biomolecular layer, which is known as protein corona. Indeed, plasma proteins adsorb on nanoparticle surface according to their abundance and affinity to the employed nanomaterial, thus even small differences between healthy and PDAC protein expression levels can be, in principle, detected. By mass spectrometry experiments, we quantified such differences and identified possible biomarkers for PDAC. Some of them are already known to exhibit different expressions in PDAC proteomes, whereas the role of other relevant proteins is still not clear. Therefore, we predict that the employment of nanomaterials and their protein corona may represent a useful tool to amplify the detection sensitivity of cancer biomarkers, which may be used for the early diagnosis of PDAC, with clinical implication for the subsequent therapy in the context of personalized medicine.

Highlights

  • Nanotechnologies represent an emerging science that has been recognized as a potential game-changer in cancer management [1]

  • We carried out a comparative analysis of the biomolecular corona (BC) formed on three liposomal formulations upon incubation with human plasma from non-oncological (CTR) and pancreatic cancer (PDAC) patients

  • After exposure to human plasma, we detected a remarkable increase of size and polydispersity for all the liposome-plasma dispersions and the measured values of zeta potential ranged within about −30 mV and −40 mV, independently on the original surface charge of the bare liposomes (Table 1)

Read more

Summary

Introduction

Nanotechnologies represent an emerging science that has been recognized as a potential game-changer in cancer management [1]. Some of these are related to the source with which NPs interact and to the environmental and experimental conditions (e.g., pH, temperature, type of biological fluid, etc.), [4] others depend on the type of used NPs (e.g., liposomes, gold, etc.) and on their chemical-physical characteristics (e.g., shape, size, electric charge, etc.) [5] These peculiarities allowed to demonstrate that the PC adsorbed to the surface of NPs is specific to different oncological pathologies but is personalized from subject to subject [6,7,8]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call